Please login to the form below

Not currently logged in
Email:
Password:

Astellas signs antibody agreement

Japan-based pharmaceutical firm Astellas is to enter a license agreement with biotechnology firm Evec for its antibody programme to fight infectious diseases

Japan-based pharmaceutical firm Astellas is to enter a license agreement with biotechnology firm Evec for its antibody programme to fight infectious diseases.

The deal will see Astellas gain worldwide rights to develop, manufacture and commercialise the related antibodies, with the programme still in a pre-clinical phase.

Evec will receive an upfront payment of 0.6bn yen, with potential milestone payments based on development and sales success of up to 13bn yen.

The company specialises in the development of a number of human monoclonal antibodies across several therapeutic areas, including cancer, inflammatory diseases and infectious diseases.

6th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics